Specific inhibition of α‐synuclein oligomer generation and toxicity by the chaperone domain Bri2 BRICHOS
Protein Science · 2024-08 · 33 (8)
DOI: 10.1002/pro.5091 ↗At a glance
Journal article in Protein Science, published online on 2024-07-09. Written by Laurène Adam and 12 co-authors. Institution: Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden. Major MEDLINE topics: alpha-Synuclein, Molecular Chaperones. Cited 12 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: FORMAS, Swedish Society for Medical Research, Alzheimer Foundation.
Abstract (original language)
Protein misfolding and aggregation are involved in several neurodegenerative disorders, such as α‐synuclein (αSyn) implicated in Parkinson's disease, where new therapeutic approaches remain essential to combat these devastating diseases. Elucidating the microscopic nucleation mechanisms has opened new opportunities to develop therapeutics against toxic mechanisms and species. Here, we show that naturally occurring molecular chaperones, represented by the anti‐amyloid Bri2 BRICHOS domain, can be used to target αSyn‐associated nucleation processes and structural species related to neurotoxicity. Our findings revealed that BRICHOS predominantly suppresses the formation of new nucleation units on the fibrils surface (secondary nucleation), decreasing the oligomer generation rate. Further, BRICHOS directly binds to oligomeric αSyn species and effectively diminishes αSyn fibril‐related toxicity. Hence, our studies show that molecular chaperones can be utilized as tools to target molecular processes and structural species related to αSyn neurotoxicity and have the potential as protein‐based treatments against neurodegenerative disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
- Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Aarhus C, Denmark.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.
ORCID profiles: Rakesh Kumar, Jan Johansson, Axel Abelein
Funding
- FORMAS
- Swedish Society for Medical Research
- Alzheimer Foundation
- Åke Wiberg Foundation
- Magnus Bergvall Foundation
- Åhlen Foundation
- KI Research Foundation
- Foundation for Geriatric Diseases KI
Cite
APA
Adam, L., Kumar, R., Arroyo-Garcia, L. E., Molenkamp, W. H., Nowak, J. S., Klute, H., Farzadfard, A., Alkenayeh, R., Nielsen, J., Biverstål, H., Otzen, D. E., Johansson, J., & Abelein, A. (2024). Specific inhibition of α‐synuclein oligomer generation and toxicity by the chaperone domain Bri2 BRICHOS. Protein Science, 33(8). https://doi.org/10.1002/pro.5091
Vancouver
Adam L, Kumar R, Arroyo-Garcia LE, Molenkamp WH, Nowak JS, Klute H, et al. Specific inhibition of α‐synuclein oligomer generation and toxicity by the chaperone domain Bri2 BRICHOS. Protein Science. 2024;33(8). doi:10.1002/pro.5091
BibTeX
@article{Adam2024,
author = {Adam, Laurène and Kumar, Rakesh and Arroyo-Garcia, Luis Enrique and Molenkamp, Willem Hendrik and Nowak, Jan Stanislaw and Klute, Hannah and Farzadfard, Azad and Alkenayeh, Rami and Nielsen, Janni and Biverstål, Henrik and Otzen, Daniel E and Johansson, Jan and Abelein, Axel},
title = {Specific inhibition of α‐synuclein oligomer generation and toxicity by the chaperone domain Bri2 BRICHOS},
journal = {Protein Science},
year = {2024},
volume = {33},
number = {8},
doi = {10.1002/pro.5091}
}
EUVIMED